CA-THERMO-FISHER
Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic Regulations (IVDR) 2017/746 in the European Union. These compliance updates will enable cytogenetics testing laboratories to adapt to the latest medical device safety and efficacy frameworks and conformity assessments.
“Thermo Fisher’s unparalleled commitment to driving innovation in chromosomal microarrays has led to advancement of cytogenetic testing capabilities,” said Kevin Lowitz, vice president and general manager, microarray, at Thermo Fisher Scientific. “The compliance updates to the CytoScan Dx Assay kit and ChAS Dx software provide our customers in the EU with solutions that can help them maintain high patient safety standards and meet EU IVD regulatory requirements.”
Advancements in chromosomal microarrays (CMAs) have greatly expanded the capabilities of cytogenetics testing in recent years, including the ability to yield insights into genetic risk factors and disorders that are essential to understanding reproductive health. As an in vitro diagnostic CMA test for postnatal analysis, the CytoScan Dx Assay aids in the identification of underlying genetic causes of neurological and dysmorphic disorders in children. The assay enables users to accurately detect numerous chromosomal variations at higher resolution and greater coverage than conventional methods. It has demonstrated to improve diagnostic yield by an incremental 12.5% compared to G-banded karyotyping.
ChAS Dx is a powerful, intuitive software that simplifies cytogenetic analysis, visualization, and reporting of chromosomal aberrations across the genome. ChAS Dx provides whole-genome support for CytoScan Dx Arrays with flexible parameters and data formats, as well as direct access to multiple leading external genetic databases. The advanced data analysis software is available to all CytoScan Dx customers at no additional cost.
The complete IVDR compliant CytoScan Dx Cytogenetics Suite is a sample to insight solution that includes the CytoScan Dx Array, a reagent kit, the Applied Biosystems™ GeneChip™ System 3000 Dx platform for array processing, and user-friendly ChAS Dx software.
To learn more about the complete IVDR compliant CytoScan Cytogenetics Suite, please visit www.thermofisher.com/microarrayivd.
For In Vitro Diagnostic Use.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530659960/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AV’s JUMP 20 Selected by Danish Defence Acquisition and Logistics Organisation for Tactical UAS Program of Record10.2.2025 15:10:00 CET | Press release
AeroVironment (AV), through its wholly owned subsidiary Arcturus UAV, has been awarded a contract by the Danish Defence Acquisition and Logistics Organisation (DALO) with a contract ceiling value of $181 million to deliver the JUMP® 20 medium uncrewed aircraft system (UAS) to the Danish Armed Forces. This 10-year program of record will equip the Danish Army with JUMP 20 systems to enhance intelligence, surveillance, and reconnaissance (ISR) operations, reinforcing AV’s position as a global leader in advanced autonomous solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210680163/en/ AV to supply its JUMP 20 uncrewed aircraft system to the Danish Armed Forces through new program of record (Photo: AeroVironment) JUMP 20 is a vertical take-off and landing (VTOL), fixed-wing UAS with 13+ hours of endurance and an operational range of 185 km (115 mi). Runway independent, the system is easily storable and transportable,
Tigo Energy Expands Predict+ for Utility Analytics as Platform Approaches 10X Annual Growth10.2.2025 15:00:00 CET | Press release
Predict+ platform surpasses 140,000 meters under management globally, expands advanced feature set, and brings machine learning-powered energy consumption and production prediction to utilities in Europe and North America. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo”), a leading provider of intelligent solar and energy software solutions, today announced a set of powerful enhancements to the Predict+ platform that gives utilities deep insight into grid demand, renewable generation, and energy market dynamics. Designed to enhance the accuracy, scalability, and robustness of energy forecasting with up to 97.5% accuracy through machine learning and artificial intelligence, the platform leverages smart meter consumption data to predict precise grid production and consumption forecasts. Predict+ helps energy providers streamline operations, reduce volatility, and maximize performance. Since the first quarter of 2024, the Predict+ platform has grown from 15,000 to 140,000 meters under management
Veridas Takes the Lead in the Race Against Gen AI Fraud with New Advanced Injection Attack Capability10.2.2025 15:00:00 CET | Press release
Generative AI is fueling a new wave of identity fraud, making digital security more critical than ever. In response, Veridas, a global leader in AI-driven identity verification, has introduced an advanced injection attack detection capability to combat the growing threat of synthetic identities. This new feature strengthens fraud prevention by combining injection detection with liveness verification across face, voice, and document authentication. Injection Attacks: The Hidden Threat in Digital Fraud According to the Veridas Identity Fraud Report 2024, 85% of financial fraud cases now involve synthetic identities. The UK government recently declared deepfakes as the ‘greatest challenge of the online age’, highlighting these growing risks. Fraudsters inject deepfakes and synthetic data directly into identity systems—bypassing device sensors entirely. Traditional fraud detection only analyzes what’s presented (images, videos, or voices), not whether the device is compromised. Veridas has
Zayed Sustainability Prize Opens Global Call for Transformative Solutions10.2.2025 14:21:00 CET | Press release
The US $5.9 million fund empowers small and medium sized enterprises, nonprofits, and high schools to develop sustainable solutions and transform their communitiesAcross 6 key categories – Health, Food, Energy, Water, Climate Action and Global High Schools – winners will be recognised for their groundbreaking impact and receive the prestigious award The UAE’s Zayed Sustainability Prize, a portfolio entity of Erth Zayed Philanthropies which has impacted 400 million lives worldwide by advancing innovative solutions to pressing global challenges, has officially announced its call for submissions for 2026. Marking 17 years of continued support and empowerment for the next generation of sustainability champions, the Prize invites small to medium enterprises (SMEs), nonprofit organisations, and high schools to submit their projects in six distinct categories: Health, Food, Energy, Water, Climate Action, and Global High Schools. This press release features multimedia. View the full release he
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer10.2.2025 14:00:00 CET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers. Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies. AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials. “This collaboration with Lilly represents a significant milestone for AdvanCell, recognizi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom